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Abstract
Background Because antileukotrienes may inhibit
inflammation, it is plausible that montelukast administered
for a long time could suppress skin wheal and flare reac-
tion, and thus, it should be discarded prior to the tests. This
study assessed the effect of long-lasting treatment with
montelukast alone or in combination with antihistamines
on wheal and flare in skin pricks tests (SPT) in patients
sensitized to perennial allergens.
Methods We conducted a 32-week, double-blind, pla-
cebo-controlled, cross-over and randomized trial that
implicated two arms: arm A, 20 patients received levoce-
tirizine, montelukast with or without levocetirizine or
placebo; arm B, 20 patients received desloratadine, mont-
elukast with or without desloratadine or placebo. All
treatment periods lasted 6 weeks and were separated by
2-week washouts. At baseline and on the last day of each
treatment period, SPT were performed in all participants.
Results Both levocetirizine and desloratadine in mono-
therapy, or in combination with montelukast, were
effective in reducing wheal and flare in SPT. Monotherapy
with montelukast did not change the size of the wheal for
either histamine or for house dust mites, in either arm of
the study, but significantly reduced the size of flare for
histamine in arm A. Addition of montelukast to antihista-
mine did not exceed efficacy of monotherapy with
antihistamine in both arms of the study.
Conclusions Since the size of wheal determines the
results of SPT, montelukast, even taken for a long time,
does not have to be discarded prior to the tests.
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Introduction
Skin prick tests (SPT) are commonly used to confirm
sensitization to a wide spectrum of environmental aller-
gens. SPT help to diagnose the underlying cause of rhinitis,
asthma or urticaria, and are required to recommend
appropriate prophylaxis or for qualification for immuno-
therapy [1, 2]. Since early wheal and flare reactions result
mainly from histamine released from degranulating mast
cells, it is obvious that antihistamines are more or less able
to inhibit this reaction [3].
Since montelukast, a potent and selective leukotriene
receptor antagonist, suppresses allergic inflammation [4–
8], improves control of asthma [8] and reduces symptoms
of seasonal [4, 5] and perennial [6, 7] allergic rhinitis (AR),
it is possible that it may inhibit skin response to allergens
measured in skin prick tests. Although guidelines for skin
prick testing do not recommend discontinuation of
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montelukast before the SPT [1, 2], most studies relied on
assessment of wheal and flare reactions after the single
dose [9] or a very short-term treatment with montelukast
[10]. Furthermore, there were studies that confirmed
gradually increasing improvement of AR symptoms in the
course of long-lasting treatment with montelukast [7, 11,
12] or combination of montelukast with antihistamine [11].
Therefore, it is plausible that one dose or short treatment
with montelukast may not affect SPT, whereas long lasting
treatment with this agent administered alone or in combi-
nation with antihistamine due to the increasing efficacy and
immunomodulative properties may affect the skin response
in SPT.
In this study, we aimed to determine the influence of
montelukast administered for 6 weeks as monotherapy or
added to antihistamine on the size of wheal and flare in
SPT of patients with allergic rhinitis sensitized to perennial
allergens, in relation to placebo as well as to monotherapy
with desloratadine or levocetirizine.
Study design
This study was designed as a prospective, double-blind,
randomized, cross-over and controlled with placebo,
including two arms with a 2-week run-in period and four
treatment periods each lasting for 6 weeks separated by
2-week washouts.
Patients were recruited in our outpatient clinic over
4 months (June–September) and study was performed
between September and March.
Study included male and female patients, aged
18–65 years with at least 2 years history of mild to severe
persistent allergic rhinitis who were sensitized to peren-
nial allergens relevant to Central Europe (HDM: house
dust mite, cat and dog), confirmed by a positive history
and positive results of skin prick tests, whereas patients
who suffered from skin diseases that prevented execution
and interpretation of skin prick tests, who were treated
with systemic steroids or immunomodulative medica-
ments, as well as patients who were current smokers, with
infection within 6 weeks preceding the study or with
neoplasmatic disease and severe diseases, were excluded
from the study. Pregnant and breast-feeding women were
excluded too. Patients could not use an allergen-specific
immunotherapy or any anti-allergic medications during
the course of the study except the study medication.
Xylomethasoline (0.1 %) nasal drops were allowed as a
rescue medication.
After a two-week run-in period, all eligible patients (30
female, 10 male, mean age was 28.9 ± 2.7) were assigned
randomly into group A (n = 20) receiving either levoce-
tirizine (5 mg tablet one daily in the evening) or
montelukast (10 mg tablet once daily in the evening) or a
combination of montelukast and levocetirizine (in the
evening) or placebo, or to group B (n = 20) receiving
either desloratadine (10 mg tablet once daily in the even-
ing) or montelukast (10 mg tablet once daily in the
evening), or a combination of montelukast and deslorata-
dine (in the evening) or placebo (5 mg saccharose in starch
pills, one daily in the evening). Medications were admin-
istered in a cross-over and blinded manner.
Both at baseline and on the last day of each treatment
period, skin prick tests were done for each participant.
All patients signed written informed consent and the
study protocol was approved by the ethical committee of
the Medical University in Lodz.
The principal endpoint of this study was the size of
wheal and flare in skin prick tests after the 6 weeks of
treatment, either with monotherapy with antihistamine
(desloratadine or levocetirizine) and montelukast, or with
combination therapy, which included antihistamine and
montelukast in relation to the baseline test and placebo.
Skin prick tests
Skin prick tests with 11 common allergens (Allergopharma
J. Ganzer KG, Reinbeck, Germany) were performed for
each patient, with histamine (10 mg/ml) as a positive and
diluent as a negative control. Results were regarded as
positive when the mean wheal diameter (assessed as a sum
of the largest diameter and its perpendicular measurement)
was greater than or equal to 3 mm. Since all patients were
sensitized to the house dust mites, results of the SPT were
presented for Dermatophagoides pteronyssinus and farinae
in relation to the histamine.
Statistical methods
The distribution of the results was determined with the
Shapiro–Wilk normality test, while a Mann–Whitney test
was used to compare groups and one-way analysis of
variance (Anova) was done to compare results in each arm
on different visits. A p \ 0.05 was considered as statisti-
cally significant. The mean with standard error of the mean
(SEM) was provided. Statistica 5.1 PL for Windows soft-
ware (StatSoft Polska, Cracow, Poland) was used for
analyses.
Results
All randomized patients completed four treatment periods,
and only two patients were lost to follow-up. All partici-
pants were sensitized to house dust mites and six patients
were additionally sensitized to cat and dog allergens.
Although sensitization to seasonal allergens was present in
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some patients, it was not essential in relation to HDM.
Patients’ baseline characteristics are presented in Table 1.
Generally, the mean size of the wheal and flare was the
biggest at baseline. The placebo did not affect the size of
skin reactions both to histamine and HDM in patients
evaluated in the arm A and B (Table 2; Figs. 1, 2, 3).
Levocetirizine administered as monotherapy or in
combination with montelukast in arm A and monotherapy
with desloratadine, as well as concomitant treatment with
desloratadine and montelukast in arm B were the most
effective treatment options of inhibiting the size of wheal
and flare in SPT. There were no significant differences
between antihistamine taken alone or in combination with
montelukast (Table 2; Figs. 1, 2, 3).
If montelukast was administered as monotherapy, it did
not change the size of the wheal for either histamine or for
HDM, in either arm of the study. However, montelukast
significantly reduced the size of flare in the SPT with
histamine in arm A and slightly, but not significantly
(p = 0.052), reduced the size of flare for D. pteronyssinus
in arm B. Administration of montelukast in combination
with antihistamine had no effect on the size of wheal and
flare in comparison to monotherapy with antihistamine in
both arms of the study (Table 2; Figs. 1, 2, 3).
Discussion
The results of this study demonstrate that long-term ther-
apy with montelukast, which is administered in
monotherapy or concomitantly with the levocetirizine or
desloratadine, does not affect formation of wheals in SPT,
nor does it potentiate the inhibitory effect of antihista-
mines. Since the diameter of the wheal underlies the
assessment of results of SPT, slight inhibition of flare by
montelukast does not affect outcomes of the test; thus
montelukast, even administered for a long time, does not
have to be discarded before the skin prick test.
The formation of wheals and flares in skin prick tests
result from an immunoglobulin E-dependent basophils and
mast cells activation, marked by the release of inflamma-
tory mediators, including histamine [1]. Histamine induces
capillary dilation, increases vascular permeability, stimu-
lates nociceptors responsible for pain, and further causes
eosinophil chemotaxis to the inflamed tissue. As a result,
the exudation enters the skin and causes swelling accom-
panied by itching [1, 2]. Although it is unlikely that
montelukast, a potent leukotriene receptor antagonist,





Number of subjects 20 20
Mean age 23.65 ± 2.1 34.1 ± 2.69
Sex F:M 14:6 16:4
Ethnic origin Caucasian (100 %) Caucasian (100 %)
Duration of persistent
allergic rhinitis (years)
5.65 ± 0.85 7.85 ± 1.32
Severity of AR (according
to ARIA)
Moderate/severe Moderate/severe
Data are expressed as mean value ± SEM
Table 2 Flare reaction in patients treated with: montelukast alone; levocetirizine alone; placebo or with the combination of montelukast and
levocetirizine (group A) and montelukast alone; desloratadine alone; placebo or with the combination of montelukast and desloratadine (group B)
Histamine D. pteronyssinus D. farinae
A
Baseline 13.35 ± 1.88 11.2 ± 2.71 13.9 ± 2.9
Placebo 11.3 ± 1.66 11.25 ± 2.79 12.9 ± 2.5
Levocetirizine 2.05 ± 0.67** 4.6 ± 1.35** 4.75 ± 1.67**
Montelukast 8.95 ± 1.65* 11.5 ± 2.74 14.55 ± 2.73
Montelukast ? levocetirizine 2.75 ± 0.58** 5.15 ± 1.89** 5.5 ± 1.84**
B
Baseline 13.1 ± 1.53 10.6 ± 2.9 10.75 ± 2.53
Placebo 11.65 ± 1.73 8.55 ± 2.42 9.25 ± 2.28
Desloratadine 3.7 ± 1.2** 5.6 ± 2.2** 4.45 ± 1.8**
Montelukast 13.26 ± 1.8 9.35 ± 2.46 11.1 ± 2.46
Montelukast ? desloratadine 4.4 ± 1.32** 6.1 ± 2.13** 5.75 ± 2.02**
Values ± SEM
n Number of subjects
* p \ 0.05 vs. baseline
** p \ 0.01 vs. baseline, placebo and montelukast
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directly affects release of histamine from basophils and
mast cells [10, 13], it is well documented that it possesses
other anti-inflammatory properties [14–18], and may
increase the clinical effect during the treatment [11, 12].
Thus, if taken for a long time, it could alter the inflam-
matory response of the skin.
Montelukast has been able to modify the skin response;
however, the number of studies supporting this finding is
still obscure. In rats exposed to water avoidance stress,
5-day treatment with montelukast decreased the number of
both degranulated and mature granulated mast cells in the
dermis [19]. In humans, montelukast significantly delayed
the occurrence of late skin responses, which constitute very
frequent side effects of specific immunotherapy [9], and
decreased the severity of severe hypersensitivity reactions
to platinum in patients undergoing rapid desensitization
[20]. In patient with delayed pressure urticaria, addition of
montelukast to antihistamine resulted in better
improvement regarding the suppression of the challenge
test and clinical improvement [21].
Despite its anti-inflammatory properties and clinical
efficacy, a single dose [9] or 1-week treatment with
montelukast [10, 22] did not significantly suppress both
wheal [9, 10, 22] and flare [9, 10] at any time point com-
pared with placebo. Furthermore, in this field, the efficacy
of short treatment with montelukast was always inferior to
efficacy of antihistamines [9, 10]. What is more, mont-
elukast as add-on therapy to antihistamine did not bring
any additional benefits compared to monotherapy with
antihistamine [10].
Similarly in this study, the long-lasting treatment with
montelukast did not alter the size of the wheal in SPT. The
efficacy of montelukast was comparable to placebo, and
significantly lower than efficacy of monotherapy with
levocetirizine and desloratadine in arm A and B, respec-
tively. Furthermore, montelukast did not change the mean
Fig. 1 Mean diameter of wheal
for histamine in patients treated
in montelukast/levocetirizine
arm (graph A), and montelukast/
desloratadine arm (graph B).
Data are expressed as
mean ± SEM; m ? l,
montelukast with levocetirizine;
m ? d, montelukast with
desloratadine; **p \ 0.01
Fig. 2 Mean diameter of wheal
for Dermatophagoides
pteronyssinus in patients treated
in montelukast/levocetirizine
arm (graph A), and montelukast/
desloratadine arm (graph B).
Data are expressed as
mean ± SEM; m ? l,
montelukast with levocetirizine;
m ? d, montelukast with
desloratadine; **p \ 0.01
Fig. 3 Mean diameter of wheal for Dermatophagoides farinae SPT
in patients treated in montelukast/levocetirizine arm (graph A), and
montelukast/desloratadine arm (graph B). Data are expressed as
mean ± SEM; m ? l, montelukast with levocetirizine; m ? d,
montelukast with desloratadine; **p \ 0.01
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diameter of flare for HDM in arm A and B and histamine in
arm B, but significantly reduced the size of the flare to
histamine in arm A when compared to baseline. However,
the efficacy of montelukast was lower than the efficacy of
levocetirizine and desloratadine and comparable to placebo
at any time point of the study. Also, addition of mont-
elukast did not potentiate effects of antihistamines.
The results of our study confirm that montelukast, which
may modify tissue infiltration and inflammatory milieu,
and subsequently may modify the late phase of allergic
inflammation, does not seem to affect release of histamine
from activated mast cells and basophils. Therefore, mont-
elukast, even if is taken for a long time, does not need to be
discontinued before allergen skin testing. The reduction of
flare for histamine in patients treated with montelukast
results from a small number of participants, rather than
anti-inflammatory properties of montelukast, and does not
affect reading of SPT where the mean size of the wheal is
important.
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